A phase 1 clinical trial evaluated the safety and immunogenicity of the Nipah virus vaccine (HeV-sG-V) in healthy adults aged 18 to 49 years. The study was single-center, randomized, observer-blinded, and placebo-controlled, testing three vaccine doses: 10 µg, 30 µg, and 100 µg. A total of 192 people participated, of which 173 met the criteria for analysis according to the protocol. The vaccine was well tolerated, no serious adverse events related to vaccination were recorded. All three doses induced an immune response, with higher doses showing a stronger response. Antibodies appeared within one month after vaccination and persisted mainly after two doses. The results suggest that HeV-sG-V has potential for use in reactive outbreak control and as a preventive vaccine against Nipah virus. The study was funded by CEPI and approved by the ethics committee of Cincinnati Children's Hospital Medical Center[2][3][5].